Maria Pernas
Overview
Explore the profile of Maria Pernas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
338
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Valenzuela-Fernandez A, Cabrera-Rodriguez R, Casado C, Perez-Yanes S, Pernas M, Garcia-Luis J, et al.
Biomedicines
. 2022 Sep;
10(9).
PMID: 36140273
In the absence of antiviral therapy, HIV-1 infection progresses to a wide spectrum of clinical manifestations that are the result of an entangled contribution of host, immune and viral factors....
2.
Cabrera-Rodriguez R, Perez-Yanes S, Montelongo R, Lorenzo-Salazar J, Estevez-Herrera J, Garcia-Luis J, et al.
Int J Mol Sci
. 2022 Jun;
23(11).
PMID: 35682862
The transactive response DNA-binding protein (TARDBP/TDP-43) influences the processing of diverse transcripts, including that of histone deacetylase 6 (HDAC6). Here, we assessed TDP-43 activity in terms of regulating CD4+ T-cell...
3.
Perez-Yanes S, Pernas M, Marfil S, Cabrera-Rodriguez R, Ortiz R, Urrea V, et al.
Front Microbiol
. 2022 Apr;
13:763039.
PMID: 35401460
The understanding of HIV-1 pathogenesis and clinical progression is incomplete due to the variable contribution of host, immune, and viral factors. The involvement of viral factors has been investigated in...
4.
Moyano A, Blanch-Lombarte O, Tarancon-Diez L, Pedreno-Lopez N, Arenas M, Alvaro T, et al.
Retrovirology
. 2022 Mar;
19(1):6.
PMID: 35346235
Background: Long-Term Non-Progressors (LTNPs) are untreated Human Immunodeficiency virus type 1 (HIV-1) infected individuals able to control disease progression for prolonged periods. However, the LTNPs status is temporary, as viral...
5.
Colomer-Lluch M, Kilpelainen A, Pernas M, Pena R, Ouchi D, Jimenez-Moyano E, et al.
J Virol
. 2021 Oct;
96(1):e0149921.
PMID: 34668779
Human immunodeficiency virus type 1 (HIV-1) viremic nonprogressors (VNPs) represent a very rare HIV-1 extreme phenotype. VNPs are characterized by persistent high plasma viremia and maintenance of CD4 T-cell counts...
6.
Beltran-Pavez C, Bontjer I, Gonzalez N, Pernas M, Merino-Mansilla A, Olvera A, et al.
J Virol
. 2021 Oct;
96(1):e0134321.
PMID: 34668778
Longitudinal studies in HIV-1-infected individuals have indicated that 2 to 3 years of infection are required to develop broadly neutralizing antibodies. However, we have previously identified individuals with broadly neutralizing...
7.
Dominguez-Molina B, Tarancon-Diez L, Milanes-Guisado Y, Genebat M, Resino S, Rodriguez C, et al.
J Int AIDS Soc
. 2020 Sep;
23(9):e25607.
PMID: 32909370
Introduction: HIV-controllers have the ability to spontaneously maintain viraemia at low or undetectable levels in the absence of antiretroviral treatment. Furthermore, HIV-controllers seem to have a superior capacity to spontaneously...
8.
Casado C, Pernas M, Rava M, Ayerdi O, Vera M, Alenda R, et al.
AIDS Res Hum Retroviruses
. 2020 Jul;
36(11):896-904.
PMID: 32722915
Data on the prevalence of double infection (DI) in HIV individuals are lacking in Spain. To fill this gap, we analyzed the prevalence of DI in a cohort of men...
9.
Casado C, Galvez C, Pernas M, Tarancon-Diez L, Rodriguez C, Sanchez-Merino V, et al.
Sci Rep
. 2020 Feb;
10(1):1902.
PMID: 32024974
Elite controllers (EC) represent a small subset of HIV-1-infected people that spontaneously control viral replication. However, natural virological suppression and absence of immune dysfunction are not always long-term sustained. We...
10.
Docando F, Casado C, Pernas M, Mota-Biosca A, Lopez-Galindez C, Olivares I
Arch Virol
. 2020 Feb;
165(3):683-690.
PMID: 32002668
In the search for new antiviral therapies against human immunodeficiency virus type 1 (HIV-1), several cellular targets are being investigated. Ataxia telangiectasia and Rad3-related protein (ATR) has been implicated in...